Business Description
Percheron Therapeutics Ltd
NAICS : 325412
SIC : 2834
ISIN : AU0000317281
Description
Percheron Therapeutics Ltd is a biotechnology company, developing and commercializing antisense pharmaceuticals for large unmet markets in rare diseases. The company operates into two operating segment: ATL1102 and ATL1103. Key revenue is generated from ATL1102.
Financial Strength
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 296.68 | |||||
| Equity-to-Asset | 0.64 | |||||
| Piotroski F-Score | 3/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -12.6 | |||||
| 3-Year EPS without NRI Growth Rate | -9.4 | |||||
| 3-Year FCF Growth Rate | -10.1 | |||||
| 3-Year Book Growth Rate | 18.6 | |||||
| Future 3-5Y EPS without NRI Growth Rate | -42.18 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 1.83 | |||||
| 9-Day RSI | 5.32 | |||||
| 14-Day RSI | 9.82 | |||||
| 6-1 Month Momentum % | -8.64 | |||||
| 12-1 Month Momentum % | 34.55 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 2.81 | |||||
| Quick Ratio | 2.81 | |||||
| Cash Ratio | 2.3 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -11 | |||||
| Shareholder Yield % | -174.02 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -99.92 | |||||
| ROA % | -75.51 | |||||
| ROIC % | -4288.18 | |||||
| ROC (Joel Greenblatt) % | -14833.2 | |||||
| ROCE % | -99.68 | |||||
| Years of Profitability over Past 10-Year | 1 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 0.7 | |||||
| Price-to-Tangible-Book | 0.7 | |||||
| EV-to-EBIT | 0.35 | |||||
| EV-to-EBITDA | 0.36 | |||||
| EV-to-FCF | 0.55 | |||||
| Price-to-Net-Current-Asset-Value | 0.7 | |||||
| Price-to-Net-Cash | 0.7 | |||||
| Earnings Yield (Greenblatt) % | 284.49 | |||||
| FCF Yield % | -132.94 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Percheron Therapeutics Ltd Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil A$) | |||
| EPS (TTM) (A$) | -0.014 | ||
| Beta | 0.55 | ||
| Volatility % | 73.3 | ||
| 14-Day RSI | 9.82 | ||
| 14-Day ATR (A$) | 0.005643 | ||
| 20-Day SMA (A$) | 0.0529 | ||
| 12-1 Month Momentum % | 34.55 | ||
| 52-Week Range (A$) | 0.005 - 0.14 | ||
| Shares Outstanding (Mil) | 1,087.44 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Percheron Therapeutics Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Percheron Therapeutics Ltd Stock Events
| Event | Date | Price(A$) | ||
|---|---|---|---|---|
| No Event Data | ||||
Percheron Therapeutics Ltd Frequently Asked Questions
What is Percheron Therapeutics Ltd(ASX:PER)'s stock price today?
The current price of ASX:PER is A$0.01. The 52 week high of ASX:PER is A$0.14 and 52 week low is A$0.01.
When is next earnings date of Percheron Therapeutics Ltd(ASX:PER)?
The next earnings date of Percheron Therapeutics Ltd(ASX:PER) is .
Does Percheron Therapeutics Ltd(ASX:PER) pay dividends? If so, how much?
Percheron Therapeutics Ltd(ASX:PER) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers